An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA

Trial Profile

An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma; Tuberous sclerosis
  • Focus Adverse reactions; Expanded access
  • Acronyms EFFECTS
  • Sponsors Novartis
  • Most Recent Events

    • 30 Aug 2014 According to the European Clinical Trials Database record, status changed from recruiting to completed.
    • 14 Apr 2012 Additional locations (Czech Republic, Germany, Greece, Italy, Spain) added as reported by European Clinical Trials Database.
    • 25 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top